Analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a research note issued on Friday. The firm set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a report on Friday, November 15th.
View Our Latest Analysis on Aethlon Medical
Aethlon Medical Price Performance
About Aethlon Medical
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- Trading Stocks: RSI and Why it’s Useful
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Nebius Group: The Rising Star in AI Infrastructure
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.